New Drug Development Center, DGMIF, 80 Cheombok-ro Dong-gu, Daegu, 701-310, Korea.
Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Center for Life Science, Beth Israel Deaconess Medical Center, Harvard Medical School, Room 0408, 330 Brookline Avenue, Boston, MA, 02215, USA.
Arch Pharm Res. 2016 Dec;39(12):1609-1620. doi: 10.1007/s12272-016-0821-x. Epub 2016 Aug 29.
Protein phosphorylation and post-phosphorylation events regulate many cellular signaling pathways. Peptidyl-prolyl isomerase (Pin1) is the only peptidyl-prolyl cis/trans isomerase that interacts with numerous oncogenic or tumor suppressive phosphorylated proteins, causes conformational changes in target proteins, and eventually regulates the activities of such proteins. These alterations in activity play a pivotal role in tumorigenesis. Since Pin1 is overexpressed and/or activated in various types of cancers, and the dysregulation of proline-directed phosphorylation contributes to tumorigenesis, Pin1 represents an attractive target for cancer therapy. This review will describe the role of Pin1 in cancer and the current status of Pin1 inhibitor development.
蛋白质磷酸化和磷酸化后事件调节许多细胞信号通路。肽脯氨酰顺/反异构酶(Pin1)是唯一与众多致癌或肿瘤抑制性磷酸化蛋白相互作用的肽脯氨酰顺/反异构酶,导致靶蛋白构象变化,并最终调节这些蛋白的活性。这些活性的改变在肿瘤发生中起着关键作用。由于 Pin1 在各种类型的癌症中过度表达和/或激活,并且脯氨酸定向磷酸化的失调导致肿瘤发生,因此 Pin1 代表了癌症治疗的一个有吸引力的靶点。本文将描述 Pin1 在癌症中的作用以及 Pin1 抑制剂开发的现状。